IMMUNEONCO-B(01541): The Phase III clinical trial of IMM01 (Tepadurimab) in combination with Azacitidine for first-line treatment of CMML has completed dosing for the first patient.

IMMUNEONCO-B (01541) announced that the phase III clinical trial of IMM01 (Tilsotolimod) in combination with azacitidine for the first-line treatment of chronic myelomonocytic leukemia (CMML) has successfully completed dosing for the first patient. This is the world's first registered Phase III clinical study of a differentiation cluster 47 (CD47) targeted drug for the first-line treatment of CMML. The company owns the global intellectual property and commercialization rights of IMM01 (Tilsotolimod). As of the date of this announcement, the company has a patent family for IMM01 (Tilsotolimod), including authorized patents in China, the United States, Japan, and the European Union.